Conventional Squamous Cell Carcinoma

- Squamous carcinomas are nearly always positive for cytokeratin.
- Common cytokeratin expression in squamous carcinomas includes AE1/AE3, CK5, CK5/6, CK14, and CK17.
- Nuclear p63 expression is common in squamous carcinomas but is not completely specific for squamous tumors.
- Cytokeratin stains can help detect subtle metastatic foci, particularly in the post-treatment setting in lymph nodes.

Basaloid Squamous Cell Carcinoma

- The differential diagnosis for basaloid squamous cell carcinoma (BSCC) includes adenoid cystic carcinoma and small cell neuroendocrine carcinoma.
- The best markers to differentiate these are p63 and neuroendocrine markers: BSCC will be positive for cytokeratin and p63 and negative for most neuroendocrine markers.

Verrucous Carcinoma and Papillary Squamous Cell Carcinoma

- Verrucous carcinoma (VC) and papillary squamous cell carcinoma (PSCC) have a similar gross appearance, but VC has a pushing leading edge and no atypia, whereas PSCC shows cytologic atypia and more typical invasion.
- No diagnostic immunohistochemical markers can be used to identify VC or PSCC.

Spindle Cell Carcinoma

- The diagnosis of spindle cell carcinoma (SPCC) requires the identification of a component of squamous neoplasia or epithelial differentiation of the spindle cells.
- Multiple cytokeratin and epithelial markers may be necessary to show positive staining in the spindle cells, but up to 30% of SPCCs will not stain for cytokeratin in the spindle cell component.

Olfactory Neuroblastoma

- Olfactory neuroblastoma (ONB) is composed of small round blue cells that grow in a lobular or diffuse pattern.
- The tumor cells are positive for neuroendocrine markers, and up to 30% can be positive for cytokeratin.
- Sustentacular cells surrounding the lobules of ONB stain

Sinonasal Undifferentiated Carcinoma

- Sinonasal undifferentiated carcinoma is composed of high-grade, small- to medium-sized cells with prominent mitoses and necrosis.
- The tumor cells are positive for cytokeratin and may be positive for EMA.
- Neuroendocrine markers are rarely positive; when they are, staining should be only focal.

Malignant Melanoma

- Mucosal melanomas stain with similar panels of markers to their cutaneous counterparts (S-100, HMB45, tyrosinase).
- Rare cases of mucosal melanomas have been reported to be positive for CAM5.2.

Small Cell Neuroendocrine Carcinoma

Neuroendocrine carcinomas are positive for cytokeratins and for typical neuroendocrine markers, such as chromogranin and synaptophysin.

Invasive-Ectopic Pituitary Adenoma

- Pituitary lesions can present in the sinonasal tract, either as invasive adenomas or as ectopic tumors.
- Functional pituitary adenomas can be found to express a variety of hormones, such as growth hormone, prolactin, thyroid-stimulating hormone, adrenocorticotropic hormone, or follicle-stimulating hormone.

Rhabdomyosarcoma

- Rhabdomyosarcoma can rarely arise in the sinonasal tract.
- This tumor stains similar to soft tissue counterparts, with desmin and myogenin positivity.

Ewing's Sarcoma and Peripheral Neuroectodermal Tumor

- Ewing's sarcoma/peripheral neuroectodermal tumor is composed of uniform round cells with a lobular configuration.
- The tumor cells are positive for vimentin and CD99.

Intestinal-Type Adenocarcinoma

- Intestinal-type adenocarcinomas resemble colorectal carcinomas at the histologic level.
- ITACs usually stain positive with CK7, CK20, and CDX2.

Glomangiopericytoma

- Glomangiopericytomas are unique lesions that occur exclusively within the sinonasal tract.
- They are strongly positive for SMA and vimentin, but less commonly for CD34.

Neuroendocrine Tumors

- The three categories of neuroendocrine tumors (carcinoid, atypical carcinoid, and small cell neuroendocrine carcinoma) are distinguished from one another mainly on the basis of histologic appearance.
- The immunophenotype of these tumors includes positivity for neuroendocrine markers and for cytokeratins.
- TTF-1 may be positive in these extrapulmonary neuroendocrine/ small cell carcinomas.

Mucoepidermoid Carcinoma

- Three cell populations can generally be seen in mucoepidermoid carcinoma (MEC): epidermoid cells, mucous cells, and intermediate cells.
- No immunohistochemical stains are sensitive or specific for MEC in routine diagnostic use.
- p63 nuclear expression resides in the epidermoid component.

Polymorphous Low-Grade Adenocarcinoma

- Polymorphous low-grade adenocarcinoma (PLGA) is predominantly a tumor of minor salivary glands of the oral cavity.
- Myoepithelial cells are sparse or absent in PLGA, but S-100 protein is usually diffusely positive.

Adenoid Cystic Carcinoma

Adenoid cystic carcinoma has three growth patterns:

cribriform, tubular, and solid.

- These tumors are composed of both an epithelial cell component and a myoepithelial component, and immunohistochemical stains can be used to identify each.
- High-grade transformation is accompanied by a change to pure epithelial cells and a complete loss of myoepithelial cells. These tumors are often p53 positive.

Epithelial-Myoepithelial Carcinoma

- Epithelial-myoepithelial carcinoma is a biphasic tumor, composed of well-organized epithelial cells growing in ducts and tubules and surrounded by myoepithelial cells; these are often encircled by dense hyalinized stroma.
- Both the epithelial and the myoepithelial cell components can be identified with immunohistochemical stains.

Salivary Duct Carcinoma

- Salivary duct carcinoma (SDC) resembles some breast carcinomas histologically.
- SDC is positive for androgen receptor and HER2/neu;
 HER2/neu is often amplified by FISH.

Low-Grade Cribriform Cystadenocarcinoma

- Low-grade cribriform cystadenocarcinoma is a rare tumor that grows in a variety of patterns.
- This tumor is positive for S-100 in a strong and diffuse manner.
- Because it is an *in situ* carcinoma, the nests of tumor cells are surrounded by a well-defined myoepithelial cell layer that can be detected with typical myoepithelial cell immunohistochemical markers.

Paragangliomas

- Paragangliomas of the head and neck can occur in rather specific locations.
- The tumor cells are positive for chromogranin and synaptophysin and negative for cytokeratin.
- The sustentacular, supporting cells are positive for S-100.
- Malignancy cannot be predicted by histologic features alone; only metastasis identifies a tumor as being malignant.

Metastatic Tumors

- Metastatic tumors are most commonly attributed to head and neck primary tumors, but sites below the clavicle are also possible.
- A histologically guided immunohistochemical staining panel can often help to identify the tumor type.
- Determining the source of a metastatic carcinoma in the head and neck can be difficult or impossible, even with immunohistochemical stains, and will often require clinical and radiologic correlation.

TABLE 9.11	P.11 Immunohistochemical Staining Pattern for Tumors in the Differential Diagnosis for Paragangliomas								
Stain	Carcinoid Tumor	Paraganglioma	Medullary	Melanoma	Renal Cell	Metastatic (Thyroid CA, Carcinoma, or Lung Carcinoma)			
Chromogranin	+	+	+	N	N	+			
Synaptophysin	+	+	S	N	N	+			
Cytokeratin 7	S	N	N	N	S	+			
Cytokeratin 20	S	N	N	N	N	+			
CEA	S	Unk	+	N	S	+			
S-100	N	+ (sustentacular)	N	+	S	N			
Calcitonin	N	N	+	N	N	N			
TTF-1	N	N	+	N	N	+			

^{+,} almost always positive; N, negative; S, sometimes positive.

TABLE 9.9	Intest	Intestinal-type Adenocarcinoma versus Metastatic Adenocarcinoma of Colon								
	CK7	CK20	CEA	CDX-2	Chromogranin	MUC2	MUC5			
ITAC	S	+	S	+	S	+	R-N			
Colon	R	+	+	+	R	+	R-N			

^{+,} almost always positive; N, negative; R, rare, and focally positive; S, sometimes positive.

TABLE 9.8	Differential Diagnosis of Invasive-Ectopic Pituitary Adenoma							
Feature		Pituitary Adenoma	Olfactory Neuroblastoma	Paraganglioma	Carcinoid			
Synaptophysin		+	+	+	+			
CAM 5.2		+	S	N	S			
S-100 (sustenta	cular cells)	N	+	+	R			
Hormones		+	N	N	S			
Pit-1		+	unknown	unknown	unknown			

^{+,} almost always positive; N, negative; R, rare, and focally positive; S, sometimes positive.

TABLE 9.7	TABLE 9.7 Sinonasal Undifferentiated Carcinoma versus Undifferentiated Nasopharyngeal Carcinoma (UNPC)						
Feature	SNUC	UNPC					
Location	Sinonasal tract	Nasopharynx					
Clinical	Large primary, ± cervical lympl	n nodes Small primary, positive cervical lymph nodes					
X-ray	Marked destruction and spread site of origin	I beyond Little destruction or spread beyond site of origin					
Growth	Trabeculae, nests, sheets	Syncytial					
Cells	Hyperchromatic to vesicular nu or without nucleoli	rclei with Large, vesicular nuclei with prominent nucleoli					
Mitoses	Very prominent	Not prominent					
Necrosis	Very prominent	Not prominent					
Vascular invasio	n Very prominent	Not prominent					
Lymphocytes	Absent to mild	Heavy infiltrate					
Epstein-Barr viru	us (USA) Negative	Positive					
CK5/6 & 13	Negative	Positive					
CK7	±	Negative					

TABLE 9.4	Olfactory Neuroblastoma (ONB) versus Sinonasal Undifferentiated Carcinoma (SNUC)					
Feature		ONB	SNUC			
Age (average)		40-45	58			
Site		Roof of nasal cavity	Multiple sites			
Prognosis/surviv	val	60%-80% 5 yr	18-mo median			
Ocular-cranial r	nerve	Occasional	Common			
Anaplasia		Occasional	Common			
Mitoses		Variable	Numerous			
Necrosis		Occasional	Prominent			
Vascular invasio	n	Occasional	Prominent			
Neurofibrillary s	stroma	Common	Absent			
Homer Wright	rosettes	Common	Absent			
Keratin		25%-35%	90%			
EMA		0%	65%			
NSE		80%-100%	50%			
S-100		60%	0%-15%			
Synaptophysin		100%	0%			
Neurosecretory granules		Numerous	Rare			

ONB is typically negative but may infrequently focally express low-molecular-weight cytokeratin.

TABLE 9.3	Immunohistochemical Staining of Round Cell Tumors of the Sinonasal Tract								
Tumor	(CK	EMA	LCA	Synaptophysin	HMB-45	Desmin	Vimentin	CD99
SNUC		+	+	N	N	N	N	N	N
ONB		S	N	N	+	N	N	N	N
NPC		+	+	N	N	N	N	N	N
Lymphoma		N	N	+	N	N	N	+	S
Melanoma		N	N	N	N	+	N	+	N
Rhabdomyosarco	oma	N	N	N	N	N	+	+	N
Small cell carcino	oma	+	+	N	+	N	N	N	N
ES/PNET		N	N	N	+	N	N	+	+

CK, cytokeratin; EMA, epithelial membrane antigen; LCA, leukocyte common antigen; NPC, nasopharyngeal carcinoma; ONB, olfactory neuroblastoma; ES/PNET, Ewing's sarcoma/peripheral neuroectodermal tumor; SNUC, sinonasal undifferentiated carcinoma. +, almost always positive; S, sometimes positive; N, negative.

TABLE 9.2	.2 Differentiating Basaloid Squamous Cell Carcinoma from Adenoid Cystic and Small Cell Neuroendocrine Carcinoma								
	Tumor Type								
Antibody Mark	Basaloid Squamous Cell Adenoid Cystic Small Cell Neuroendocrine Antibody Marker Carcinoma Carcinoma								
Cytokeratin	+	+	+						
Chromogranin	N	N	+						
S-100	S	+ (peripheral, myoepithelial)) N						
p53	+	S	+						
Ki-67	High	Low	High						
C-kit	S	+	+						
p63	+ (diffuse and strong)	+ (peripheral, myoepithelial)	S (

^{+,} almost always positive; N, negative; S, sometimes positive.

TABLE 9.1	TABLE 9.1 Antibodies Used in the Evaluation of Head and Neck Specimens							
Antibody	Source	Dilution	Antibody	Source	Dilution			
Androgen recep	otor Biogenex	1:2000	CK19	Novocastro	1:50			
Bcl-2	Dako	1:200	CK20	Dako	1:40			
β-Catenin	BD Transduction		CK903	Sigma	1:20			
	Laboratories		Ki-67	AMAC	1:200			
Calponin	Dako	1:200	Laminin	Sigma	1:20			
Calretinin	Zymed	1:750	LCA	Dako	1:20			
CD31	Dako	1:40	Melan-A	Novocastro	1:40			
CD34	Dako	1:800	Microphthalmic	Neomarkers	1:40			
CD99	Dako	1:20	transcription					
CD x 2	Bio Genex	1:50	factor					
CEA	Boehringer-Mannheim	1:4000	Muscle-specific actin (HHF-35)	Enzo	1:8000			
Chromogranin	Boehringer-Mannheim	1:4000	MUC2	Novocastro	1:100			
Desmin	Biogenex	1:2000	MUC5	Novocastro	1:150			
EMA	Dako	1:400	Myogenin	Novocastro	1:30			
FLI-1	Santa Cruz	1:40	Neuron-specific	Bio Genes	1:450			
GFAP	Dako	1:300	enolase					
HER2/neu	Dako	1:100	Pit-1	Santa Cruz				
HMB-45	Biogenex	1:60	p53	Oncogene	1:160			
AE1/3	Boehringer-	1:100	p63	Neomarkers	1:200			
	Mannheim		S-100 protein	Dako	1:1000			
CAM5.2	Becton-Dickinson	1:200	Smooth muscle	Dako	1:80			
CK4	Novocastra	1:100	actin					
CK5/6	Roche	1:20	Synaptophysin	Boehringer- Mannheim	1:40			
CK7	Biogenex	1:800	Thomasa		1.50			
CK8	Novocastro	1:60	Thyroid transcription	Neomarkers	1:50			
CK10	Novocastro	1:50	factor					
CK13	Dako	1:100	Tyrosinase	Novocastro	1:20			
CK14	Novocastro	1:40	Vimentin	Biogenex	1:20			




FIGURE 10.24 Algorithm of head and neck endocrine tumors.